Current Position: Home >> Nablib®-Antibody Discovery Service >> Antibody Screening Platform

Mammal display platform

Category : Antibody Screening Platform • Last Updated : 2025-12-28 11:06:52 • Hits : 48

The mammalian cell display technology is different from other types of display technologies such as phage or yeast display. It is an advanced platform designed to optimize the drugability of therapeutic antibodies. The mammalian cells in the petri dish share many common characteristics with human cells in clinical trials and cells used for antibody industrial production. This technology is a cutting-edge tool for antibody engineering such as affinity maturation and humanization.

Mammal display platform





Mammalian cell display is a powerful antibody screening tool, which can effectively balance the library capacity and sequence specificity, and ensure the physicochemical properties of antibodies, thereby improving their pharmacability.
 The mammalian display technology can not only be applied in the process of antibody screening, but also play a significant role in antibody engineering. It can be well adapted to humanization (or canine/feline source modification), affinity maturation, and PTM optimization, while maintaining excellent physicochemical properties.
 Mammalian cell display technology is not only applicable to scFv or Fab-based antibodies, but also can efficiently display complex antibody structures such as full-length IgG, VHH, and TCR. It can even directly be used in the screening of antibodies in the form of bispecific antibodies, completing the one-step construction of bispecific antibodies and affinity adjustment in a seamless manner.
Screening of the full-spectrum configuration & The natural and powerful quality control system




Mammalian cell display technology VS Other display technologies


Application Scenario 1: Discovery of Nanobodies

Discovery of Nanobodies - Balancing Affinity and Specificity


 The extracellular domains of CD16a and CD16b are highly homologous, with only 6 scattered amino acids differing. Nanobodies with high affinity for CD16a but not binding to CD16b were obtained through screening based on the display of antibodies in mammalian cells.




Application Scenario 2: Compatibility Maturity

By mutating one amino acid in the CDR3 region, the affinity of this monoclonal antibody can be significantly enhanced (by 100 times).

The mutated monoclonal antibody enhanced the affinity for the target antigen while retaining the affinity for human antigens.

The data further confirm the excellent quality of the variant.

More affable and mature types.



Application Scenario 3: Humanization

By screening high-affinity molecules from the humanized antibody library, it is ensured to maintain and enhance the affinity of the humanized molecules.

The antigen binding capabilities of the parental molecules and the modified molecules were compared through ELISA and flow cytometry.



Application Scenario 4: Optimization of Antimolecular Antibody Neutralization Function

The antibodies that have been optimized through affinity maturation have enhanced their binding and inhibitory capabilities towards the target.




Prev Not Available
Next Nabphage Improved phage display